• Can-Fite BioPharma Ltd., of Petah-Tikva, Israel, said the FDA granted orphan drug status to CF102, its candidate in hepatocellular carcinoma (primary liver cancer). Last month, Can-Fite reported results of a Phase I/II study of CF102 suggesting the compound demonstrated a favorable safety profile in a patient population with hepatocellular carcinoma and Child-Pugh cirrhosis Classes A and B. The study also indicated the A3 adenosine receptor, which is the target of CF102, can serve as a biomarker to predict patient response to treatment. CF102 is an orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor.